

PSMA-PET Imaging to be funded through medicare in Australia from July 2022

07 April 2022 | News

MBS funding will cover the initial staging of intermediate to high-risk patients with prostate cancer and the restaging of patients with recurrent prostate cancer



Telix Pharmaceuticals Limited welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for patients with prostate cancer on the Medicare Benefits Schedule (MBS) from 1 July 2022.

MBS funding will cover the initial staging of intermediate to high-risk patients with prostate cancer and the restaging of patients with recurrent prostate cancer, commensurate with the broad clinical indications granted in Australia for Telix's prostate cancer imaging product, Illuccix.

Illuccix (Kit for the preparation of ^{68}Ga -PSMA-11) is the only regulatory approved PET agent for the diagnostic imaging of men with prostate cancer available in Australia, having received marketing approval from the Australian Therapeutic Goods Administration (TGA) in November 2021. Australia has one of the highest rates of prostate cancer in the world. In 2020, prostate cancer was the most commonly diagnosed cancer in men in Australia with approximately 18,000 new cases.